The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a mature B-cell neoplasm characterized by progressive accumulation of monoclonal B lymphocytes. CLL is considered being identical to SLL. Malignant cells seen in CLL and SLL have the same pathological and immunophenotypic features. The term CLL is used when the disease occurs mainly in the blood, while the term SLL is used when the involvement is mainly nodal.

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CACancer J Clin. 2023;73(1):17.PMID: 36633525
2. Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and otherlymphoreticular neoplasms. Cancer. 1995;75(1 Suppl):381.PMID: 8001009
3. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C,et al. Global, Regional, and National Cancer Incidence, Mortality, Years ofLife Lost, Years Lived With Disability, and Disability-Adjusted Life-yearsfor 32 Cancer Groups, 1990 to 2015: A Systematic Analysis forthe GlobalBurden of disease study. JAMA Oncol 2017; 3:524.
4. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in theUnited States by subtype and demographic characteristics, 1997-2002.Cancer Causes Control 2008; 19:379.
5. Miranda-Filho A, Piñeros M, Ferlay J, et al. Epidemiological patterns ofleukaemia in 184 countries: a population-based study. Lancet Haematol2018;5(1):e14-e24.
6. Yang S, Varghese AM, Sood N, et al. Ethnic and geographic diversity ofchronic lymphocytic leukaemia. Leukemia 2021;35(2):433-439.
7. Hallek M, Cheson BD, Catovsky D, et al. İw CLL guidelines for diagnosis,indications for treatment, response assessment, and supportivemanagement of CLL. Blood. 2018;21;131(25):2745-2760
8. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chroniclymphocytic leukemia. Blood. 1975;46(2):219-234.
9. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classificationof chronic lymphocytic leukemia derived from a multivariate survivalanalysis. Cancer. 1981;48(1):198-206.
10. Lazarian G, Munger M, Quinquenel A, et al. Clinical and biologicalcharacteristics of leukemia cutis in chronic lymphocytic leukemia: Astudy of the French innovative leukemia organization (FILO). Am JHematol. 2021;96(9):E353-E356.
11. Strati P, Uhm JH, Kaufmann TJ, et al. Prevalence and characteristics ofcentral nervous system involvement by chronic lymphocytic leukemia.Haematologica. 2016;101(4):458-65.
12. Poitou-Verkinder AL, Francois A, Drieux F, et al. The spectrum ofkidney pathology in B-cell chronic lymphocytic leukemia / smalllymphocytic lymphoma: a 25-year multicenter experience. PLoSOne2015;10(3):e0119156
13. Baer MR, Stein RS, Dessypris EN. Chronic lymphocytic leukemiawith hyperleukocytosis. The hyperviscosity syndrome. Cancer.1985;56(12):2865-2869
14. Diehl LF, Ketchum LH. Auto immune disease and chronic lymphocyticleukemia: auto immune hemolytic anemia, püre red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25(1):80-97.
15. Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia innewly diagnosed chronic lymphocytic leukemia: Natural history, clinicalcorrelates, and outcomes. Cancer. 2015;121(17):2883-2891
16. Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Using smudge cells onroutine blood smears to predict clinical outcome in chronic lymphocyticleukemia: a universally-available prognostic test. Mayo ClinProc.2007;82(4):449-453
17. Rawstron AC, Villamor N, Ritgen M, et al. International standardizedapproach for flow cytometric residual disease monitoring in chroniclymphocytic leukaemia. Leukemia. 2007;21(5):956-964.
18. Ben-Ezra J, Burke JS, Swartz WG, et al. Small lymphocytic lymphoma: aclinicopathologic analysis of 268 cases. Blood. 1989;73(2):579-587
19. Thomas R, Ribeiro I, Shepherd P, et al. Spontaneous clinical regression inchronic lymphocytic leukaemia. Br J Haematol. 2002;116(2):341-345
20. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensiveprognostic index for patients with chronic lymphocytic leukemia. Blood.2014;124(1):49-62
21. Moreno C, Hodgson K, Ferrer G, et al. Auto immune cytopenia in chroniclymphocytic leukemia: prevalence, clinical associations, and prognosticsignificance. Blood. 2010;116(23):4771-4776.
22. Zenz T, Vollmer D, Trbusek M, et al. European Research Initiative onCLL (ERIC). TP53 mutation profile in chronic lymphocytic leukemia:evidence for a disease specific profile from a comprehensive analysis of268 mutations. Leukemia. 2010;24(12):2072-2079.
23. International CLL-IPI working group. An international prognostic indexfor patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
24. Montserrat E, Vinolas N, Reverter JC, et al. Chronic lymphocytic leukemiain early stage "smoldering" and "active" forms in chronic lymphocyticleukemia. In: Scientific Advances and Clinical Developments, ChestonBD (Ed), Marcel Decker, New York 1993. p.281.
25. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. JNatlCancerInst. 1999;91(10):861-868
26. Morrison WH, Hoppe RT, Weiss LM, et al. Small lymphocyticlymphoma. J ClinOncol. 1989;7(5):598-606.
27. Moreno C, Greil R, Demirkan F et al. Ibrutinib plus obinutuzumabversus chlorambucil plus obinutuzumab in first-line treatment ofchronic lymphocytic leukaemia (iLLUMINATE): a multicentre,randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
28. Shanafelt TD, Wang XV, Kay NE et al. Ibrutinib-rituximab orchemoimmunotherapy for chronic lymphocytic leukemia. N Engl JMed. 2019;381:432-43
29. Sharman JP, Egyed M, Jurczak W et al. Acalabrutinib with or withoutobinutuzumab versus chlorambucil and obinutuzumab for treatmentnaïve chronic lymphocytic leukemia (ELEVATE TN): a randomised,controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291.
30. Weirda WG et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-linetreatment of chronic lymphocytic leukemia (CLL)/smalllymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) resultsfromthe MRD cohort of the Phase 2 CAPTIVATE study. AmericanSociety of Hematology Annual Meeting 2020: Oral Presentation.
Volume 1, Issue 3, 2023
Page : 59-67